ABIVAX Société Anonyme (ABVX)
ABVXNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$88.53
+0.0600 (+0.07%) today
At the close, Nov 10, 4:00 PM ET. After hours $89.90 -0.11%
- Market cap
- $7.85bn
- P/E
- –
- EPS, last 4 quarters
- $-6.06
- Dividend yield
- –
- Day range
- $87.60 to $91.38
- 52-week range
- $69.81 to $148.83
- Average volume
- 1.13m
- Previous close
- $88.47
Analysts
9 coveringBuy8 buy, 1 hold, 0 sell
Targets a year out average $160.56, +81.4% from here
Earnings
next estimate $-1.27Next report Dec 21, 2026
Sep 2025
–
Dec 2025
+30.0%
Mar 2026
+33.6%
Jun 2026
-58.3%
estimate reported, and the surprise
Financials
No quarterly figures from the source.
News
8 latest- Notable ETF Inflow Detected - VEA, GFL, ABVX, SHOPBNK Invest · Oct 6, 2026
- Abivax H1 Net Loss Widens; Plans Obefazimod NDA For Ulcerative Colitis By End Of 2026 RTTNews · Sep 22, 2026
- 4 Biotech Stocks to Watch as Potential Takeover TargetsZacks · Sep 18, 2026
- Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's WhyZacks · Sep 8, 2026
- VGK, ABVX, BORR: Large Outflows Detected at ETFBNK Invest · Aug 6, 2026
- Should You Buy Abivax SA Sponsored ADR (ABVX) After Golden Cross?Zacks · Jul 10, 2026
- 3 Soaring Stocks That May Have More Upside AheadThe Motley Fool · Jul 7, 2026
- Abivax: Wall Street Catches Up to the DataMarketBeat · Jul 7, 2026
The company
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- Europe
- Website
- abivax.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.